Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion
- PMID: 17004249
- DOI: 10.1002/lt.20872
Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion
Abstract
Long-term results of organ transplantation are still limited by serious side effects of immunosuppressive drugs. A major issue, therefore, is to elaborate novel therapeutic protocols allowing withdrawal or minimization of immunosuppressive therapy after transplantation. We report on 3 patients prospectively enrolled in an original protocol designed to promote graft acceptance in living donor liver transplantation, using posttransplant conditioning with high doses of antithymocyte globulin followed by injection of donor-derived stem cells. In 2 patients, early immunosuppression withdrawal was possible, without subsequent graft deterioration. In these 2 cases, in vitro studies showed indices of immunological tolerance as assessed by specific hyporesponsiveness to donor alloantigens in mixed lymphocytes culture. In the third patient, acute rejection rapidly occurred after discontinuation of immunosuppression, and minimal immunosuppression has to be maintained during long-term follow-up. In this case, a clearly distinct immunoreactive profile was observed as compared to tolerant patients, as no specific modulation of the antidonor response was observed in vitro. Of note, no macrochimerism could be detected in any of the 3 patients during the follow-up. In conclusion, these clinical observations demonstrated that, despite the absence of macrochimerism, donor stem cells infusion combined with recipient conditioning may allow early immunosuppression withdrawal or minimization after liver transplantation.
Comment in
-
Tolerance for organ recipients: a clash of paradigms.Liver Transpl. 2006 Oct;12(10):1448-51. doi: 10.1002/lt.20905. Liver Transpl. 2006. PMID: 17004264 No abstract available.
Similar articles
-
Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.Transpl Immunol. 2004 Sep-Oct;13(2):139-46. doi: 10.1016/j.trim.2004.05.004. Transpl Immunol. 2004. PMID: 15380544
-
Repeating intraportal donor-specific transfusion may induce tolerance following adult living-related donor liver transplantation.Hepatogastroenterology. 2003 May-Jun;50(51):601-6. Hepatogastroenterology. 2003. PMID: 12828042
-
Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells.Transplantation. 2009 May 15;87(9 Suppl):S91-5. doi: 10.1097/TP.0b013e3181a2dee6. Transplantation. 2009. PMID: 19424019
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Tolerance induction in clinical transplantation.Transpl Immunol. 2004 Sep-Oct;13(2):117-30. doi: 10.1016/j.trim.2004.05.009. Transpl Immunol. 2004. PMID: 15380542 Review.
Cited by
-
Understanding, predicting and achieving liver transplant tolerance: from bench to bedside.Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):719-739. doi: 10.1038/s41575-020-0334-4. Epub 2020 Aug 5. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32759983 Review.
-
Strategies for Liver Transplantation Tolerance.Int J Mol Sci. 2021 Feb 24;22(5):2253. doi: 10.3390/ijms22052253. Int J Mol Sci. 2021. PMID: 33668238 Free PMC article. Review.
-
Cell-Mediated Therapies to Facilitate Operational Tolerance in Liver Transplantation.Int J Mol Sci. 2021 Apr 13;22(8):4016. doi: 10.3390/ijms22084016. Int J Mol Sci. 2021. PMID: 33924646 Free PMC article. Review.
-
Utilization of Treg Cells in Solid Organ Transplantation.Front Immunol. 2022 Feb 4;13:746889. doi: 10.3389/fimmu.2022.746889. eCollection 2022. Front Immunol. 2022. PMID: 35185868 Free PMC article. Review.
-
Cell transplantation-based regenerative medicine in liver diseases.Stem Cell Reports. 2023 Aug 8;18(8):1555-1572. doi: 10.1016/j.stemcr.2023.06.005. Stem Cell Reports. 2023. PMID: 37557073 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical